United States News Todas as matérias

Femasys (NASDAQ:FEMY) announced that the U.S. FDA approved its modular premarket approval submission approach for FemBloc, the company’s investigational non-surgical permanent birth control technology.

Kiora Pharmaceuticals (NASDAQ:KPRX) licensed South Korean development and commercialization rights for its retinal therapy KIO-301 in ophthalmic indications to Chong Kun Dang Pharmaceutical (CKD).

Biodexa (NASDAQ:BDRX) announced that 87 of a planned 168 subjects have been enrolled in its registrational Phase 3 Serenta trial evaluating eRapa in Familial Adenomatous Polyposis (FAP).

Cosmos Health (NASDAQ:COSM) reported record second-quarter 2026 revenue of $18.99 million, up 28.8% year over year, with first-half revenue increasing 29.7% to $36.91 million.

Top Wealth Group Holding (NASDAQ:TWG) reported unaudited first-half 2026 revenue of $6.1 million, up 48% from $4.2 million a year earlier, driven mainly by expansion of its premium wine distribution business.

Teva Pharmaceuticals (NYSE:TEVA) announced that the U.S. FDA accepted its New Drug Application for ecopipam (EBS-101) and granted Priority Review for pediatric Tourette syndrome.

Intelligent Bio Solutions (NASDAQ:INBS) reported fiscal 2026 revenue of $4.2 million, up 38% year over year, driven by growth in its installed reader base and consumable cartridge sales.

Chemomab Therapeutics (NASDAQ:CMMB) reported second-quarter 2026 results and progress on its proposed all-stock merger with Scipher Medicine, with Chemomab shareholders expected to own about 32% of a combined company valued at $150 million.

Galmed Pharmaceuticals (NASDAQ:GLMD) announced that its wholly owned subsidiary Colospan completed a first-in-human feasibility study of a colon tissue quality assessment platform in 32 colorectal cancer patients undergoing elective surgery.

Veralto (NYSE:VLTO) signed a definitive agreement to acquire Cleanwater1 for $465 million, with an estimated net purchase price of $452 million after tax benefits.

Datavault AI (NASDAQ:DVLT) reported second-quarter 2026 revenue of $6.7 million, up $5 million or 287% year over year, as the company expanded its data monetization and tokenization platforms.

Antalpha (NASDAQ:ANTA) reported unaudited second-quarter 2026 revenue of $12.2 million, down 28% year over year, mainly due to lower technology financing fees following the wind-down of the Cango facility.

Viking Holdings (NYSE:VIK) reported second-quarter 2026 revenue of $2.19 billion, up 16.5% year over year, with adjusted EBITDA increasing 18.2% to $748.4 million.

TJX Companies (NYSE:TJX) reported second-quarter fiscal 2027 net sales of $15.2 billion, up 5% year over year, with consolidated comparable sales increasing 4%.

ZIM Integrated Shipping Services (NYSE:ZIM) reported second-quarter 2026 revenue of $1.78 billion, up 9% year over year, with net income increasing to $64 million from $24 million.

Aurora Cannabis (NASDAQ:ACB) confirmed that Curaleaf Holdings has commenced an unsolicited takeover bid for all Aurora common shares, offering implied consideration of US$4 per share.

Analog Devices (NASDAQ:ADI) reported record fiscal third-quarter 2026 revenue of $4.02 billion, up 40% year over year, with growth led by Data Center and Industrial markets.

IQSTEL (NASDAQ:IQST) reported first-half 2026 revenue of $207 million, up about 59% year over year from approximately $130 million, with gross profit increasing 26% to about $4.8 million.

Merck (NYSE:MRK) and Moderna (NASDAQ:MRNA) announced positive Phase 3 results from the INTerpath-001 trial, with intismeran autogene combined with KEYTRUDA meeting its primary recurrence-free survival endpoint and key secondary distant metastasis-free survival endpoint in patients with resected stage IIB-IV melanoma.

Target (NYSE:TGT) reported second-quarter 2026 net sales of $26.5 billion, up 5.3% year over year, as comparable sales increased 3.8% with traffic growth of 3.6%.

TOYO (NASDAQ:TOYO) reported $118.2 million in second-quarter revenue driven by increased deliveries of solar products.

IDEAYA Biosciences (NASDAQ:IDYA) announced a clinical collaboration with Genentech to evaluate IDE892 with GDC-7035 (RG6620) in patients with MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma (PDAC).

Estée Lauder Companies (NYSE:EL) reported fiscal 2026 net sales of $15 billion, up 5% year over year, as organic sales increased 3% and adjusted operating margin expanded to 11.2%.

Lowe’s (NYSE:LOW) reported second-quarter 2026 sales of $26 billion, up from $24 billion, while net earnings held at $2.4 billion.